© 2026 Sinochem Nanjing Corporation,
All Right Reserved
|
HS Code |
424348 |
As an accredited 4-Bromo-1H-Indazole-3-Carboxylic Acid factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | |
| Shipping | |
| Storage |
Competitive 4-Bromo-1H-Indazole-3-Carboxylic Acid prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615371019725 or mail to admin@sinochem-nanjing.com.
We will respond to you as soon as possible.
Tel: +8615371019725
Email: admin@sinochem-nanjing.com
Flexible payment, competitive price, premium service - Inquire now!
Many research professionals look for reliable building blocks during synthetic drug exploration, and among the growing catalog of indazole derivatives, 4-Bromo-1H-Indazole-3-Carboxylic Acid has carved out a trusted position. This compound, formally recognized by its CAS number 1160204-60-3, has earned attention in medicinal chemistry, driven by the need for selective, high-purity intermediates. I have seen firsthand how the right raw material can save weeks in the lab, especially with the constant demand for reproducibility and confidence in the outcome.
The molecule itself brings together a bromo functional group attached to the fourth position of the indazole ring, with a carboxylic acid on the third. This structural combination opens up more than just a range of synthetic routes—it also allows for direct attachment to core drug scaffolds which medicinal scientists often target while working with kinase inhibitors or designing anti-tumor agents. The fusion of bromine and carboxylic acid on the indazole ring creates points of reactivity rarely matched in other building blocks.
Stepping into the storeroom of any busy medicinal chemistry group, you’ll notice how certain aromatic acids and halogenated heterocycles sit quietly, almost always in use. 4-Bromo-1H-Indazole-3-Carboxylic Acid stands alongside them, not just for its looks but because it offers consistent results where other compounds sometimes falter. In my experience, poor solubility and batch inconsistency from lesser sources can derail a weeks-long synthetic campaign. Reputable suppliers who bring authenticated batches with LC-MS, NMR confirmation, and tight impurity controls make a difference researchers can see in their yields and purity sheets.
Medicinal chemists focus on molecules that offer more than a single shot at discovery. This product doesn’t just end up in one corner of the research world; its indazole backbone makes it part of pilot studies in oncology, CNS research, and even in broader pharmaceutical programs. The bromine on the four-position creates a perfect spot for Suzuki-Miyaura cross-coupling, making arylated derivatives straightforward to assemble. The carboxyl group on the third position is a friendly handle for amidation, turning a complex synthetic sequence into just a few predictable steps.
Plenty of indazole sources offer similar compounds, but what sets this one apart is reliability. Homegrown small-batch syntheses frequently result in dark, oily residues that resist clean crystallization, sending the chemist back to the drawing board. I’ve seen new researchers slip into the same rut—cutting corners with lesser building blocks, wasting time on middle stages that never seem to improve on repeated trials. Using a reputable, well-tested supply of 4-Bromo-1H-Indazole-3-Carboxylic Acid brings both peace of mind and a practical lift in intellectual property work, since reaction conditions and patentable routes become more reliable.
While indazole chemistry remains a field full of creative opportunities, not every substituted indazole works the same way. Chlorinated or fluorinated indazoles draw different reactivity, often requiring harsher conditions for coupling or risking unwanted side reactions. The presence of the bromo group sets 4-Bromo-1H-Indazole-3-Carboxylic Acid apart; bromine offers just the right mix of reactivity and selectivity for palladium-catalyzed cross-couplings. By comparison, iodinated analogs can be too reactive, leading to decomposition, while chlorinated ones can be sluggish or stubborn. I have seen projects stall out when substituting with less responsive halogenated indazoles.
Another aspect is the carboxylic acid on the third position, which is unusually versatile. It means medicinal chemists can quickly introduce new side chains via amide bond formation or esterification. Methyl, ethyl, or longer alkyloxy groups connect easily, allowing libraries of analogs to form in just a few short steps. With simple acids or other halogenated aromatics, achieving this flexibility often remains much more time-consuming.
Academic labs and pharmaceutical companies both battle the ripple effects of subpar material. Analytical reports on 4-Bromo-1H-Indazole-3-Carboxylic Acid from well-regarded suppliers include specifics on moisture content, residual solvents, and detailed chromatographic profiles. These metrics go beyond sales copy—they keep projects moving with minimal troubleshooting. I recall one global pharma team sifting through dozens of candidate intermediates to narrow down new kinase inhibitors. Every time we worked with high-grade lots of this compound, our reaction schemes performed as expected, minimizing the number of post-reaction purifications and sidestepping the headaches that come from minor contaminant co-elution.
Modern drug discovery depends on solid, predictable building blocks. 4-Bromo-1H-Indazole-3-Carboxylic Acid is a direct player in this field because many research routes still call for robust palladium-catalyzed couplings, especially on an indazole core. Developing advanced molecules for emerging therapies often sees the same names and structures cycle through hundreds of iterations on the benchtop. Researchers want to know their reactions work the same way every time, whether for SAR (structure-activity relationship) studies or follow-up lead optimization.
With so many next-generation therapies calling on substituted indazoles, a dependable source makes life easier for the teams pressing up against clinical deadlines. Dosing materials for pre-clinical animal studies relies entirely on quality. Safety data and pharmacokinetic profiles lose their value if upstream batches carry unpredictable profiles, trace metal residues, or inconsistent lot purities.
Speaking from actual project cycles, I’ve found that a crystalline, easily handled lot of 4-Bromo-1H-Indazole-3-Carboxylic Acid reduces waste at every stage. The compound dissolves efficiently in DMSO and other common organic solvents—crucial during high-throughput screening or repeated parallel syntheses. Some labs keep it as a powder, others as a stock solution. Its melting range remains reliable across vendors if the lab sources it from a trusted supplier, so preparative steps scale up or down without guesswork.
Plenty of researchers prefer this product during library generation, since the combination of bromo and carboxylic acid supports both late-stage diversification and upstream core construction. Medicinal chemists can protect or alkylate the acid, swap out the bromo in cross-coupling, or link fragments together with amide bonds. Before teams commit to larger analog libraries, quick transformations on the indazole scaffold often inform the next cycle of chemical optimization.
Regulated sectors don’t just expect purity—they demand proof of process and identity for every bottle that enters an R&D workflow. Each container of 4-Bromo-1H-Indazole-3-Carboxylic Acid from an established source comes with batch-specific documentation, so anyone retracing old data finds trustworthy records. In early phase development, this matters as regulatory pathways become more complex, and transparency in every part of the process grows in importance. Documented purity and supply continuity add a competitive edge you see in the progress charts of successful research teams.
Trace metals can complicate late-stage research, interfering with enzymatic or cellular assays. Analytical controls going into this compound’s manufacture reduce those risks by following best practices from both the pharmaceutical and fine chemical sectors. Sourcing partners take care to share full spectral analysis, moisture content, and batch stability to answer any compliance or reporting questions along the way.
No chemist likes opening a bottle to find unexpected clumps or traces of decomposition. I’ve worked in labs where older bottles of similar heterocycles failed long-term storage checks. With properly sealed 4-Bromo-1H-Indazole-3-Carboxylic Acid kept in dry, cool conditions, shelf lives typically stretch through multiple project cycles without additional purification. Stable lots mean less lost time—and less stress—when scaling up or repeating SAR hits for further exploration.
Stability during transport and long-term storage also gives CROs and CDMOs the flexibility to prepare for projected work, cutting down on emergency orders or the risk of overnighting new supplies. Proper packaging—airtight bottles and opaque containers—helps preserve the crystalline form, reducing exposure to atmospheric moisture or light. Project managers at specialty synthesis firms find relief in predictable performance across sample sizes, whether weighing out 100 mg for a test run or 100 g for early tox batches.
The pharmaceutical supply chain continues to experience stresses across regions. Experienced procurement teams choose compounds and vendors that consistently provide supply assurances and documentation to avoid research slowdowns. 4-Bromo-1H-Indazole-3-Carboxylic Acid’s popularity derives as much from chemical value as from the reliability of its global distribution network. In the last five years, more supplier audits and qualification visits made clear the difference between trusted partners and one-off vendors. Being able to pivot and obtain lots from several reputable sources reduces risk for multi-site research happening simultaneously across continents.
Scale-up work makes the strengths—and weaknesses—of any raw material visible. I once oversaw a week-long campaign where an alternate indazole intermediate failed to scale, leading to unexpected waste and missed timelines. In contrast, switching to a high-purity lot of 4-Bromo-1H-Indazole-3-Carboxylic Acid not only recovered yields, it actually shortened downstream purification steps. Detailed feedback from scale-up teams points to this compound’s crystalline state and reliable solubility as standout features. The subtle differences in handling, filtering, and drying influence throughput; making the right choice upstream sets the stage for reliable downstream production.
Not all analogs carry the same benefits. Brominated indazoles at other positions or with other ring substitutions have different reactivity and safety profiles. This specific combination in 4-Bromo-1H-Indazole-3-Carboxylic Acid enables careful management of byproducts and easier removal of unwanted traces in the final API (Active Pharmaceutical Ingredient). Quality in raw material translates directly into reduced risk of deviation and lower regulatory scrutiny later on.
Material price remains a factor for any project, making cost versus value a real question in each purchase. But after factoring in the time savings, increased successful outcomes, and minimized troubleshooting, researchers often find that sourcing top-tier product saves budget in the long run. Just as important, ethical sourcing stands front and center for today’s scientists. Many advanced chemistry suppliers follow transparent practices, share chain-of-custody data, and back up every batch of 4-Bromo-1H-Indazole-3-Carboxylic Acid with sustainability commitments.
Demand for green chemistry processes now influences raw material choices more than ever. Leading vendors engage in solvent recycling, waste minimization, and reduced energy consumption, which supports larger environmental goals without compromising product quality or reproducibility. Transparent labeling and supply data meet requirements from procurement teams committed to sustainable operations.
While 4-Bromo-1H-Indazole-3-Carboxylic Acid holds proven utility now, future applications are likely to open new pathways and uses. Creative researchers continue to push the boundaries of what indazole-based intermediates deliver, from tweaking CNS-targeted therapies to advancing kinase inhibitor research. Looking ahead, improvements in manufacturing may bring down cost or expand the range of custom derivatives direct from trusted raw material stocks.
A major, ongoing challenge is synthesizing analogs with similar reliability or creating new functional groups that expand the toolbox of chemical transformations. Traditional preparation methods require strong reagents and involve multiple steps, often generating significant waste. Innovations in green manufacturing and continuous-flow chemistry can solve these pain points by reducing hazardous byproducts and improving overall safety, both in the lab and at production scale.
In every research cycle, from reactivity screening through to preclinical assessment, quality intermediates like 4-Bromo-1H-Indazole-3-Carboxylic Acid help move science ahead. Leveraging centuries of accumulated knowledge in organic synthesis, today’s leading scientists select tools and materials that strike the right balance of reliability, versatility, and compliance. This specific compound represents more than just another entry on a reagent shelf; it consistently delivers the traits real-world teams seek—robust reactivity, batch traceability, and a proven advantage during library construction and process development. Every time the debate comes up about whether to source a cheaper analog or invest in a quality building block, the track record of this molecule reflects a simple fact: successful outcomes start from dependable choices.
